查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1550408

血液篩檢市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、產品、地區和競爭細分，2019-2029F

Blood Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Product, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球血液篩檢市場估值為25.2 億美元，預計到2029 年預測期內將穩定成長，複合年成長率為5.25%。關重要的作用。血液篩檢是醫療保健系統中的重要步驟，可防止透過捐贈的血液傳播感染，並確保捐贈者和接受者的整體健康。隨著技術的進步和人們對血液安全重要性的日益認知，全球血液篩檢市場正在顯著成長。人們對捐血重要性的認知不斷提高，全球捐血活動不斷增多，導致捐血人數激增。因此，更需要高效、可靠的血液篩檢程序，以確保捐血者和受血者的安全。

市場概況
預測期 2025-2029
2023 年市場規模 25.2億美元
2029 年市場規模 34.5億美元
2024-2029 年複合年成長率 5.25%
成長最快的細分市場 試劑
最大的市場 北美洲

愛滋病毒、乙型和丙型肝炎以及梅毒等傳染病的全球流行凸顯了嚴格血液篩檢的重要性。先進的篩檢技術有助於及早發現這些感染，並防止其透過輸血傳播。持續的技術進步顯著提高了血液篩檢過程的效率和準確性。例如，核酸檢測（NAT）由於其高靈敏度和特異性，已成為檢測病毒感染的黃金標準。嚴格的血液安全監管架構迫使醫療機構採用最先進的篩檢技術。遵守這些法規是採用先進血液篩檢解決方案的動力。

主要市場促進因素

傳染病發生率的上升正在推動全球血液篩檢市場的發展。

不斷成長的醫療保健支出正在推動全球血液篩檢市場

主要市場挑戰

全球血液短缺

主要市場趨勢

技術進步

細分市場洞察

產品洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術分類（核酸擴增檢驗 (NAT)、ELISA、化學發光免疫分析 (CLIA) 和酵素免疫分析 (EIA)、新一代定序 (NGS)、蛋白質印跡法）
    • 依產品（試劑、儀器）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖
    • 依技術
    • 按產品分類
    • 按地區

第 5 章：亞太地區血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲血液篩檢市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按產品分類
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球血液篩檢市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Abbott Laboratories Inc.
  • Danaher Corporation (Beckman Coulter)
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Hoffman-La Roche Ltd.
  • Grifols, SA
  • Ortho-Clinical Diagnostics, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • SOFINA sa (Biomerieux)

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23223

Global Blood Screening Market was valued at USD 2.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. The global blood screening market plays a crucial role in ensuring the safety of blood transfusions and the early detection of infectious diseases. Blood screening is an essential step in the healthcare system, preventing the transmission of infections through donated blood and ensuring the overall health of both donors and recipients. With advancements in technology and a growing awareness of the importance of blood safety, the global blood screening market is witnessing significant growth. The increasing awareness about the importance of blood donation and the growing number of blood donation campaigns worldwide have led to a surge in blood donations. Consequently, there is an amplified need for efficient and reliable blood screening procedures to ensure the safety of both donors and recipients.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 2.52 Billion
Market Size 2029USD 3.45 Billion
CAGR 2024-20295.25%
Fastest Growing SegmentReagent
Largest MarketNorth America

The global prevalence of infectious diseases, including HIV, hepatitis B and C, and syphilis, underscores the significance of rigorous blood screening. Advanced screening technologies aid in the early detection of these infections, preventing their transmission through blood transfusions. Continuous technological advancements have significantly enhanced the efficiency and accuracy of blood screening processes. Nucleic acid testing (NAT), for instance, has become a gold standard for the detection of viral infections due to its high sensitivity and specificity. Stringent regulatory frameworks governing blood safety have compelled healthcare organizations to adopt state-of-the-art screening technologies. Compliance with these regulations is a driving force behind the adoption of advanced blood screening solutions.

Key Market Drivers

Rising Incidence of Infectious Diseases is Driving the Global Blood Screening Market.

In recent years, the world has witnessed a significant rise in the incidence of infectious diseases, triggering a surge in the demand for advanced diagnostic solutions. One of the critical components in combating the spread of these diseases is efficient blood screening. The global blood screening market has become a vital player in safeguarding public health by ensuring the safety of blood transfusions and donated blood products. Infectious diseases, ranging from HIV/AIDS and hepatitis to emerging threats like Zika and COVID-19, have underscored the importance of robust blood screening protocols. With globalization facilitating increased movement of people and goods across borders, the risk of infectious diseases spreading globally has intensified. Consequently, the demand for stringent blood screening measures has become paramount to prevent the transmission of infections through blood transfusions and blood-derived products. The prevalence of infectious diseases has been steadily rising, fueled by factors such as urbanization, population growth, and lifestyle changes. As a result, the need for comprehensive blood screening to identify and eliminate potentially infectious blood units has become crucial.

Advances in technology have revolutionized blood screening techniques. Nucleic acid testing (NAT), serological testing, and molecular screening methods have become more sensitive and specific, enabling the detection of a broader range of infectious agents with higher accuracy. These innovations have significantly contributed to the market's growth. Regulatory bodies across the globe have implemented stringent standards to ensure the safety of blood and blood-derived products. Compliance with these regulations has become a driving force for the adoption of advanced blood screening technologies by blood banks, hospitals, and diagnostic laboratories. Growing awareness regarding the risks associated with transfusion-transmitted infections and the importance of blood safety has led to increased public demand for safe blood products. Additionally, governments and health organizations are actively promoting blood safety initiatives, further propelling the blood screening market forward. The globalization of the blood supply chain has increased the complexity of ensuring blood safety. Blood components are often sourced from multiple regions, making it essential to implement standardized and efficient screening processes to maintain the integrity of the global blood supply.

Rising Healthcare Expenditure is Driving the Global Blood Screening Market

In recent years, the global healthcare landscape has witnessed a significant rise in expenditure, with a substantial portion allocated to diagnostic services and disease prevention. Among the various segments within the healthcare industry, the blood screening market has experienced substantial growth, propelled by increased healthcare spending. The intersection of advanced technology, rising awareness of blood-borne diseases, and the growing demand for preventive healthcare measures has positioned the blood screening market as a crucial component in the overall healthcare system. The shift towards preventive healthcare has become a global priority. Governments and healthcare organizations worldwide are increasingly investing in early detection and screening programs to identify and manage diseases at their nascent stages. Blood screening plays a pivotal role in these initiatives, allowing for the identification of various health conditions before they become more severe, thereby reducing the overall healthcare burden.

Advances in technology have revolutionized blood screening processes. Automated and high-throughput screening methods, including nucleic acid testing (NAT), enzyme immunoassay (EIA), and next-generation sequencing (NGS), have significantly improved the efficiency and accuracy of blood screening. These technological advancements, while enhancing diagnostic capabilities, have also led to increased adoption and contributed to the expansion of the blood screening market. The rising prevalence of blood-borne diseases, such as HIV, hepatitis, and various genetic disorders, has necessitated robust screening measures. Blood screening not only aids in the early detection of these diseases but also helps in preventing their transmission through blood transfusions or organ transplants. As the incidence of these diseases continues to rise, the demand for comprehensive blood screening solutions is escalating. The demographic shift towards an aging population has resulted in an increased incidence of chronic diseases. Elderly individuals often require regular monitoring and early detection of health issues, making blood screening an integral component of their healthcare regimen. The growing aging population worldwide is contributing to the overall expansion of the blood screening market. Governments and regulatory bodies are imposing more stringent standards on blood safety and transfusion medicine. Compliance with these regulations necessitates the implementation of advanced blood screening technologies to ensure the quality and safety of blood products. This increased regulatory scrutiny has further fueled the adoption of innovative screening methods, driving market growth.

Key Market Challenges

Global Blood Shortages

The primary challenge faced by the blood screening market is the insufficient availability of safe blood. Many regions around the world struggle with low blood donation rates, leading to a perpetual shortage. This shortage not only affects the ability to meet the demand for blood transfusions but also hampers the efficiency of blood screening processes. Blood shortages are not evenly distributed globally. Some regions face chronic shortages, while others may have a surplus. This geographical imbalance creates challenges for the blood screening market to establish standardized processes and technologies that can be universally applied. Economic factors, coupled with societal beliefs and cultural practices, contribute to the reluctance of individuals to donate blood. Issues such as fear, misinformation, and lack of awareness often deter potential donors, exacerbating the global blood shortage crisis. The blood screening market operates within a complex regulatory framework to ensure the safety and quality of blood products. Adhering to evolving regulations can be challenging for both established and emerging players in the industry, impacting their ability to innovate and adapt swiftly. In certain regions, technological and infrastructure gaps pose challenges for implementing advanced blood screening technologies. Limited access to cutting-edge screening methods and equipment can compromise the efficacy of the blood screening process.

Key Market Trends

Technological Advancements

In the realm of healthcare, the Global Blood Screening Market is experiencing a transformative wave driven by unprecedented technological advancements. The integration of cutting-edge technologies is enhancing the efficiency, accuracy, and scope of blood screening processes, thereby revolutionizing healthcare practices worldwide. One of the primary technological trends reshaping blood screening is the increasing use of automation and robotics. Automated systems are streamlining the screening process, minimizing human errors, and significantly improving the speed at which tests are conducted. Robotics, with their precision and speed, are enhancing sample handling and analysis, leading to quicker and more reliable results. These advancements not only increase the throughput of blood screening laboratories but also contribute to cost-effectiveness and resource optimization. The rise of molecular diagnostics and nucleic acid testing (NAT) has brought about a paradigm shift in blood screening. These technologies enable the detection of genetic material in blood samples, providing a more accurate and sensitive approach to identifying infectious diseases such as HIV, hepatitis, and others. Molecular diagnostics also play a crucial role in detecting emerging threats, ensuring the timely identification and containment of potential outbreaks. Next-generation sequencing has opened new frontiers in genomics and is increasingly being applied to blood screening. NGS allows for the rapid and comprehensive analysis of genetic material, offering insights into a wide range of genetic conditions and infectious agents. Its high throughput and ability to process multiple samples simultaneously make NGS a powerful tool in blood screening, particularly for rare diseases and personalized medicine.

Artificial intelligence and machine learning are making significant strides in healthcare, and blood screening is no exception. These technologies can analyze vast amounts of data, identify patterns, and enhance the interpretation of screening results. AI-driven algorithms can improve the accuracy of diagnoses, predict potential health risks, and optimize treatment strategies. Integrating AI and ML into blood screening processes not only improves efficiency but also contributes to more personalized and precise healthcare solutions. Advancements in point-of-care testing have brought diagnostics closer to patients, allowing for rapid screening without the need for extensive laboratory infrastructure. Portable devices equipped with advanced sensors and technologies enable real-time analysis of blood samples, providing immediate results at the patient's bedside. This not only facilitates faster decision-making by healthcare professionals but also enhances accessibility to screening in remote or resource-limited settings.

Segmental Insights

Product Insights

Based on Product, reagents emerged as the dominant player in the global market for Blood Screening in 2023. Reagent-based blood screening products are known for their high accuracy and sensitivity. The specificity of reagents ensures the detection of even low concentrations of pathogens, reducing the risk of false negatives and enhancing the overall reliability of screening results. Continuous advancements in reagent technologies have significantly improved their performance and efficiency. Cutting-edge innovations, such as nucleic acid testing (NAT) reagents, have revolutionized blood screening by providing faster and more precise results. With an increasing emphasis on blood safety and the prevention of transfusion-transmitted infections, the demand for robust blood screening solutions has surged. Reagent products, with their proven track record of accuracy, have become the preferred choice for healthcare institutions and blood banks.

Regional Insights

North America emerged as the dominated region in the global blood screening market in 2023, holding the largest market share in terms of value. North America has been quick to adopt and implement cutting-edge technologies in blood screening. The region's laboratories and diagnostic centers have embraced automation, high-throughput screening, and advanced molecular techniques, enhancing the efficiency and accuracy of blood screening processes. The integration of next-generation sequencing, polymerase chain reaction (PCR), and other molecular diagnostic tools has allowed for the early detection of infectious diseases, genetic disorders, and other health conditions. The region's well-developed healthcare infrastructure has played a crucial role in propelling North America to the forefront of the blood screening market. The presence of state-of-the-art laboratories, research facilities, and a network of well-established healthcare providers has facilitated seamless collaboration between industry stakeholders. This infrastructure not only supports routine blood screenings but also enables swift responses to emerging health threats, reinforcing the region's dominance in global blood screening.

Key Market Players

Abbott Laboratories Inc.

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthineers AG

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Report Scope:

In this report, the Global Blood Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Screening Market, By Technology:

    Nucleic Acid Amplification Test (NAT) ELISA Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) Next Generation Sequencing (NGS) Western Blotting

Blood Screening Market, By Product:

    Reagent Instrument

Blood Screening Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Screening Market.

Available Customizations:

Global Blood Screening market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Blood Screening Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting)
    • 4.2.2. By Product (Reagent, Instrument)
    • 4.2.3. By Region
    • 4.2.4. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Technology
    • 4.3.2. By Product
    • 4.3.3. By Region

5. Asia Pacific Blood Screening Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology
    • 5.2.2. By Product
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Blood Screening Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Technology
        • 5.3.1.2.2. By Product
    • 5.3.2. India Blood Screening Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Technology
        • 5.3.2.2.2. By Product
    • 5.3.3. Australia Blood Screening Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Technology
        • 5.3.3.2.2. By Product
    • 5.3.4. Japan Blood Screening Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Technology
        • 5.3.4.2.2. By Product
    • 5.3.5. South Korea Blood Screening Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Technology
        • 5.3.5.2.2. By Product

6. Europe Blood Screening Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Blood Screening Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Product
    • 6.3.2. Germany Blood Screening Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Product
    • 6.3.3. Spain Blood Screening Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Product
    • 6.3.4. Italy Blood Screening Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Technology
        • 6.3.4.2.2. By Product
    • 6.3.5. United Kingdom Blood Screening Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Technology
        • 6.3.5.2.2. By Product

7. North America Blood Screening Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Blood Screening Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Product
    • 7.3.2. Mexico Blood Screening Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Product
    • 7.3.3. Canada Blood Screening Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Product

8. South America Blood Screening Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Blood Screening Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Product
    • 8.3.2. Argentina Blood Screening Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Product
    • 8.3.3. Colombia Blood Screening Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Product

9. Middle East and Africa Blood Screening Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Blood Screening Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Product
    • 9.3.2. Saudi Arabia Blood Screening Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Product
    • 9.3.3. UAE Blood Screening Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Product

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Blood Screening Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Abbott Laboratories Inc.
    • 14.1.1. Company Snapshot
    • 14.1.2. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Danaher Corporation (Beckman Coulter)
  • 14.3. Becton Dickinson and Company
  • 14.4. Bio-Rad Laboratories, Inc.
  • 14.5. Hoffman-La Roche Ltd.
  • 14.6. Grifols, S.A.
  • 14.7. Ortho-Clinical Diagnostics, Inc.
  • 14.8. Siemens Healthineers AG
  • 14.9. Thermo Fisher Scientific, Inc.
  • 14.10.SOFINA s.a (Biomerieux)

15. Strategic Recommendations

16. About Us & Disclaimer